Ovarian Cancer: Current Treatment and Patient Management

نویسندگان

  • Bradley J. Monk
  • Paula J. Anastasia
چکیده

The decisions made by patients with ovarian cancer are tough ones. They affect the entire treatment paradigm, have long-lasting ramifications, and should be made through a collaboration between patients and clinicians, according to Bradley J. Monk, MD, of the University of Arizona Cancer Center, Phoenix, Arizona, and Paula J. Anastasia, RN, MS, AOCN®, of Cedars-Sinai Medical Center in Los Angeles, California, who spoke on the topic at JADPRO Live. Dr. Monk and Ms. Anastasia discussed the rationale behind frontline treatment decisions in advanced ovarian cancer, addressed quality-oflife concerns, and emphasized the importance of genetic testing. Patients should be carefully guided through a discussion of these different treatment strategies, according to Ms. Anastasia. Such complex conversations are best accomplished one step at a time, she maintained. Discussions about advanced disease should center upon survival in the context of hope and realistic goals. “There is a high probability of achieving a remission—not a cure—with chemotherapy,” she emphasized. Women with advanced ovarian cancer have a range of options, and no one treatment is right for every patient. For example, each woman’s cancer comprises certain cell types and molecular abnormalities, such as KRAS mutations in mucinous tumors and BRCA1/2 deficiencies in high-grade serous tumors. Treatments must be designed with these and other individual characteristics in mind. Options include surgical resection, neoadjuvant chemotherapy, weekly chemotherapy, intraperitoneal chemotherapy, and in some cases, targeted agents. The choice among them reflects the art of personalized medicine, the speakers agreed.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

I-35: Emergency Stimulation for Onco -Fertility Patients

Background Fertility preservation for female cancer patients prior to cancer therapy has emerged as an essential component of comprehensive patient care. In the US, approximately 6% of women diagnosed with invasive cancer between 2007 and 2011 that were under 45 years old. The incidence of cancers in reproductive age women signifies a need for fertility preservation options and this need is inc...

متن کامل

I-25: Gamete Cryopreservation for Cancer Patients,Ethical Considerations

Cancer patients often receive gonadotoxic treatments, such as radiation or certain chemotherapies. The doses and regimens used for treatment vary in different individuals and cancers. Recent progress has improved the survival rates of patients with cancer, often using highly aggressive therapies and combinations. This results in growing numbers of cancer survivors, some of whom will be sterile ...

متن کامل

Inm-3: Patient Management in Ultrasonography Department

Background Ultrasound has a pivotal role in imaging modality in the study of the female pelvis, and provides fundamental information in detecting uterine, ovarian, or adnexal origin, but to reach to the best results we need to use suitable procedure. The aim of this article was to describe management of infertile patient in sonography department during infertility treatment cycles.���� Material...

متن کامل

I-11: Cryopreservation and Utilization of Ovarian Tissue: When, Where and How?

In women, around 10% of cancers occur in those younger than 45 years old. Although aggressive chemotherapy/radiotherapy and bone marrow transplantation can cure more than 90% of girls and young women affected by disorders requiring such treatment, the ovaries are very sensitive to cytotoxic drugs, especially to alkylating agents. Therefore, these treatments can result in premature ovarian failu...

متن کامل

نارسایی تخمدان به‌دنبال درمان سرطان و روش‌های حفظ باروری

Primary ovarian insufficiency (POI), commonly referred to premature ovarian failure, is defined as ovarian failure before the age of 40 years. It is the loss of ovarian function caused by a process directly affecting ovaries. Cancer therapy which includes surgery, radiotherapy, and chemotherapy influence ovarian function, leading to premature menopause and loss of fertility. POI is idiopathic i...

متن کامل

Emerging treatment options for management of malignant ascites in patients with ovarian cancer

Malignant ascites affects approximately 10% of patients with recurrent epithelial ovarian cancer and is associated with troublesome symptoms, including abdominal pressure and distension, dyspnea, bloating, pelvic pain, and bowel/bladder dysfunction. To date, no effective therapy has been identified for the treatment of malignant ascites in patients with recurrent, advanced ovarian cancer. In th...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 7  شماره 

صفحات  -

تاریخ انتشار 2016